Haemonetics Corporation $HAE Stake Lowered by Riverwater Partners LLC

Riverwater Partners LLC lowered its stake in shares of Haemonetics Corporation (NYSE:HAE) by 42.6% in the third quarter, HoldingsChannel reports. The firm owned 25,780 shares of the medical instruments supplier’s stock after selling 19,143 shares during the quarter. Riverwater Partners LLC’s holdings in Haemonetics were worth $1,257,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its position in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 396 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 165 shares during the period. Versant Capital Management Inc raised its stake in Haemonetics by 216.4% during the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 567 shares in the last quarter. Byrne Asset Management LLC bought a new stake in shares of Haemonetics during the third quarter valued at about $42,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Haemonetics during the second quarter valued at about $64,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Trading Down 0.6%

Haemonetics stock opened at $68.43 on Tuesday. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08. The stock has a market cap of $3.20 billion, a P/E ratio of 20.01, a P/E/G ratio of 1.43 and a beta of 0.29. The company’s fifty day simple moving average is $79.22 and its 200-day simple moving average is $65.62.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The firm had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same quarter last year, the firm earned $1.12 earnings per share. The business’s revenue for the quarter was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, sell-side analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Barrington Research lifted their price target on shares of Haemonetics from $90.00 to $93.00 and gave the stock an “outperform” rating in a research report on Monday, January 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. Raymond James Financial restated an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a report on Friday, November 14th. Finally, CJS Securities raised Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $84.40.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.